Myelodysplastic Syndrome Clinical Trial
— MACS1574Official title:
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Verified date | March 2017 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of the study is to evaluate and compare the frequency and severity of GI adverse events in different dose administration regimens. The patient population consists of low or intermediate (int-1) risk myelodysplastic syndrome (MDS) patients with transfusional iron overload. The study patients are randomized to either a morning dose of 20 mg/kg/day deferasirox or an evening dose of the same. Patients are then followed up for 6 months for any GI events and are assessed using patient reported outcomes tools e.g. a patient diary.
Status | Terminated |
Enrollment | 12 |
Est. completion date | September 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Written informed consent prior to any screening procedures - Male or female patients = 18 years of age - Patient must weigh between 45-135 kg - Patients with low or intermediate (int-1) risk MDS, as determined by IPSS score or RA, RARS by WHO criteria. IPSS must be confirmed by a bone marrow examination within 6 months prior to study entry and must be hematologically stable Deferasirox naïve: Sexually active pre-menopausal female patients must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation Exclusion Criteria: - History or current GI disease - Systemic diseases which could prevent study treatments - Left ventricular ejection fraction< 50 % by echo cardiography - Serum creatinine > 1.2 x ULN at screening - Platelet counts < 25x 109/L except in cases where guidance is already given in the local deferasirox label - AST or ALT > 2.5 xULN at screening Other protocol-defined inclusion/exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
France | Novartis Investigative Site | Brest | |
France | Novartis Investigative Site | Caen | Cedex |
France | Novartis Investigative Site | Limoges cedex | |
France | Novartis Investigative Site | Pessac Cedex | |
France | Novartis Investigative Site | Vandoeuvre les Nancy | |
Italy | Novartis Investigative Site | Alessandria | AL |
Italy | Novartis Investigative Site | Roma | |
Italy | Novartis Investigative Site | Torino | TO |
South Africa | Novartis Investigative Site | Bloemfontein | |
Spain | Novartis Investigative Site | Madrid |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
France, Italy, South Africa, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms | Study was prematurely terminated and not powered for efficacy. Frequency of GI AEs during the overall study period is available in the AE tables reported in the safety section. | 3 months | |
Secondary | Difference in Frequency of Overall Newly Occurring GI AEs Between the Two Treatment Groups at Month 6. | Study was prematurely terminated and not powered for efficacy. | 6 months | |
Secondary | Difference in Frequency of Specific Commonly Reported GI AEs Between the Two Treatment Groups | Study was prematurely terminated and not powered for efficacy. | months 3 and 6. | |
Secondary | Difference in Severity of Overall GI AEs Between the Two Treatment Groups | Study was prematurely terminated and not powered for efficacy. | months 3 and 6. | |
Secondary | Difference in Severity of Specific Commonly Reported GI Symptoms Between the Two Treatment Groups | Study was prematurely terminated and not powered for efficacy. | months 3 and 6 | |
Secondary | Difference in Frequency and Severity of All Non-GI AEs Between the Two Treatment Groups | Study was prematurely terminated and not powered for efficacy. | months 3 and 6 | |
Secondary | the Difference Between the Time From Baseline to the First Occurrence of GI AEs Between the Two Treatment Groups | Study was prematurely terminated and not powered for efficacy. | 3 months, 6 months | |
Secondary | Difference in Severity of GI Symptoms, Bowel Habits and Level of Satisfaction From the Patient's Perspective Between the Two Treatment Groups | 3 months, 6 months | ||
Secondary | Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups | Study was prematurely terminated and not powered for efficacy. | 3 months, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT01200355 -
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Completed |
NCT03941769 -
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
|
Phase 1/Phase 2 | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT00987480 -
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
|
Phase 2 | |
Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Completed |
NCT02756572 -
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
|
Phase 2 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT02188290 -
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
|
N/A | |
Completed |
NCT02262312 -
Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome
|
Phase 0 | |
Recruiting |
NCT02330692 -
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome
|
||
Completed |
NCT01684150 -
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
|
Phase 1 |